title: Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
abstract: The immunogenicity and tolerability of virosome and of split influenza vaccines in patients with sickle cell anemia (SS) were evaluated. Ninety SS patients from 8 to 34 years old were randomly assigned to receive either virosome (n=43) or split vaccine (n=47). Two blood samples were collected, one before and one 4-6 weeks after vaccination. Antibodies against viral strains (2006) A/New Caledonia (H1N1), A/California (H3N2), B/Malaysia were determined using the hemagglutinin inhibition test. Post-vaccine reactions were recorded over 7 days. Seroconversion rates for H1N1, H3N2 and B were 65.1%, 60.4% and 83.7% for virosome vaccine, and 68.0%, 61.7% and 68.0% for split vaccine. Seroprotection rates for H1N1, H3N2 e B were 100%, 97.6% and 69.7% for virosome, and 97.8%, 97.8% and 76.6% for split vaccine. No severe adverse reactions were recorded. Virosome and split vaccines in patients with sickle cell anemia were equally immunogenic, with high seroconversion and seroprotection rates. Both vaccines were well tolerated.
authors.affiliation: Pediatric Hematology at the Federal University of São Paulo - Paulista School of Medicine, Brazil. souza.ale@terra.com.br
authors.forename: Alessandra R
authors.initials: AR
authors.lastname: Souza
authors.forename: Josefina A P
authors.initials: JA
authors.lastname: Braga
authors.forename: Terezinha M
authors.initials: TM
authors.lastname: de Paiva
authors.forename: Sandra R
authors.initials: SR
authors.lastname: Loggetto
authors.forename: Raymundo S
authors.initials: RS
authors.lastname: Azevedo
authors.forename: Lily Y
authors.initials: LY
authors.lastname: Weckx
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D022223:Vaccines, Subunit / Q000009:adverse effects / Q000276:immunology; D022721:Vaccines, Virosome / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D022223:Vaccines, Subunit; D022721:Vaccines, Virosome